Asia-Pacific Dermatology Drugs Market, By Drug Class (Corticosteroids, Retinoids, Monoclonal Antibodies, Antibiotics Agent, Antiviral Agents, Antifungal Drugs, Antihistamines Agents, Immunosuppressive Drugs, Others), Drug Type (Branded, Generics), Dermatological Diseases (Acne, Dermatitis, Psoriasis, Skin Cancer, Others), Prescription Mode (Prescription Based Drugs, Over-The-Counter Drugs), Route of Administration (Oral, Topical, Parenteral), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2030.
Asia-Pacific Dermatology Drugs Market Analysis and Size
The dermatology drugs industry has increased in the last few years due to the increasing expenditure for the skin care that accelerated the pace of expansion. Dermatology drug demand has shown great improvement to the previous year with increasing awareness for diagnostics and treatment of skin diseases. In addition, demand for dermatology drugs has risen in emerging countries with the increased spending on healthcare.
Data Bridge Market Research analyses a growth rate in the dermatology drugs market in the forecast period 2023-2030. The expected CAGR of dermatology drugs market is tend to be around 11% in the mentioned forecast period. The market value is USD 5118.7 million in 2022, and it would grow up to USD 11,796.4 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Asia-Pacific Dermatology Drugs Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Dermatological Diseases (Acne, Dermatitis, Psoriasis, Skin Cancer, Others), Drug Class (Corticosteroids, Retinoids, Monoclonal Antibodies, Antibiotics Agent, Antiviral Agents, Antifungal Drugs, Antihistamines Agents, Immunosuppressive Drugs, Others), Drug Type (Branded, Generics), Prescription Mode (Prescription Based Drugs, Over-The-Counter Drugs), Route of Administration (Oral, Topical, Parenteral), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC)
|
|
Market Players Covered
|
LUPIN (India), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (U.S.), Sanofi (France), Amgen inc. (U.S.), Lilly (U.S.), AstraZeneca (U.K.), AbbVie Inc (U.S.), Johnson & Johnson Private Limited (U.S.), LEO Pharma A/S (Denmark), Merck & Co., Inc (U.S.), Bausch Health Companies Inc (Canada) and Bristol-Myers Squibb Company (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Dermatological drugs, also termed dermatologic, are the type of products applied topically to the skin. Such drugs are widely used for the diagnosis of skin diseases and are often used to prevent some skin disorders. Although, dermatological are widely used to protect the skin for a regular skin care. Dermatology drugs are categorized into antifungal drugs, immunosuppressive drugs, corticosteroids, monoclonal antibodies, antibiotics agent, retinoids, antiviral agents, and antihistamines agents among others.
Asia-Pacific Dermatology Drugs Market Dynamics
Drivers
- Increasing Aged Population
The geriatric population loses the ability to function properly with passing age, leading to several skin illnesses. Moreover, as the person ages, the body starts to experience numerous additional issues, which includes slower wound healing, high sensitivity to ultraviolet (UV) radiation, more susceptibility to infections, and reduced subcutaneous fat. The need for dermatological medications has increased because of the likelihood of many skin conditions.
- Increasing Clinical Research
The market is anticipated to increase as more and more clinical studies are performed to evaluate the safety and efficacy of a variety of medicinal medications. For instance, in December 2021, the pharmaceutical company Amgen Inc. declared the favourable findings of a phase 3 placebo-controlled, double-blind clinical research. The main aim is to assess Otezla's effectiveness in managing moderate to severe psoriasis.
Opportunities
- Rising Incidence of Skin Diseases
The increased frequency of skin cancer and other associated skin disorders or other skin issues such as vitiligo, acne, and dermatosis along with the increasing demand of effective drugs are the most primary factors boosting the growth for this market. Fungal infection and acne were more prevalent in the adolescent age group, resulting in about 17.4% and 30.4%, respectively. Around 84.5 million Americans, one in four, were hugely impacted by skin disease. Acne is the most common skin condition in the U.S., affecting more than 50 million Americans every year. Acne typically begins in puberty and affects several adolescents and young adults. As per the records of the World Psoriasis Day consortium, around 125 million people globally which means that 2 to 3 percent of the total population suffer from psoriasis,. Thus, this boosts the market growth.
Restraints/Challenges
- High Cost of Treatment
The increased expenditure related with these drugs hamper the market growth. Numerous market players make huge investments in the manufacturing of new drugs to increase the recovery process; which increases the cost. Thus, this factor obstructs the market growth as the treatment options are not viable for all the economic groups.
- Lack of Reimbursement Policies
A huge lack of reimbursement for several dermatology drugs is expected to limit the market growth. Both public and private payers do not recompense majority of the treatment services. The increased cost of such services vary greatly and there cannot be any standardization. Thus, this factor hampers the market growth.
This dermatology drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the dermatology drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Asia-Pacific Dermatology Drugs Market Scope
The dermatology drugs market is segmented on the basis of drug class, dermatological diseases, prescription mode, route of administration, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Dermatological Diseases
- Acne
- Dermatitis
- Psoriasis
- Skin Cancer
- Others
Prescription mode
- Prescription Based Drugs
- Over Counter Drugs
Drug Class
- Corticosteroids
- Cortisone
- Hydrocortisone
- Prednisone
- Astringents
- Alum
- Acacia
- Sage
- Anti-Inflammatory & Antipruritic Drugs
- Ibuprofen
- Naproxen
- Aspirin
- Anti-Infective/Antibacterial Drugs
- Penicillins and β-lactamase inhibitors
- Cephalosporins
- Antifungal Drugs
- Clotrimazole
- Econazole
Route of Administration
- Topical
- Oral
- Parenteral Administration
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Dermatology Drugs Market Regional Analysis/Insights
The dermatology drugs market is analyzed and market size insights and trends are provided by dermatological diseases, drug class, drug type, prescription mode, route of administration, and distribution channel as referenced above.
The major countries covered in the dermatology drugs market report are China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC).
Japan is dominating the market because of the growing focus on the dermatological health and growing awareness about good health and increasing spending on healthcare.
China is having the highest market share due to increasing spending on health care in the country as demand for branded drugs is increasing. Also, the increasing awareness for diagnostics and treatment of skin diseases combined with the growing prevalence of skin diseases in the country has increased the demand for dermatology drugs.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of asia-pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Asia-Pacific Dermatology Drugs Market Share Analysis
The dermatology drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, asia-pacific presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to dermatology drugs market.
Key players operating in the dermatology drugs market include:
- LUPIN (India)
- Novartis AG (Switzerland)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Pfizer Inc. (U.S.)
- Sanofi (France)
- Amgen inc. (U.S.)
- Lilly (U.S.)
- AstraZeneca (U.K.)
- AbbVie Inc (U.S.)
- Johnson & Johnson Private Limited (U.S.)
- LEO Pharma A/S (Denmark)
- Merck & Co., Inc (U.S.)
- Bausch Health Companies Inc (Canada)
- Bristol-Myers Squibb Company (U.S.)
SKU-